Foresight in clinical proteomics: current status, ethical considerations, and future perspectives

With the advent of robust and high-throughput mass spectrometric technologies bioinformatics tools to analyze large data sets, proteomics has penetrated broadly into basic translational life sciences research. More than 95% FDA-approved drugs currently target proteins, most diagnostic tests are protein-based. The introduction clinic, for instance guide patient stratification treatment, is already ongoing. Importantly, ethical challenges come with this success, which must also be adequately addressed by medical communities. Consortium members H2020 European Union-funded initiative: Proteomics Infrastructure Consortium-providing access (EPIC-XS) met at Core Technologies Life Sciences (CTLS) conference discuss emerging role implementation in clinic. discussion, involving leaders field, focused on current status, related challenges, future efforts required make a more mainstream technology clinical Here we report that discussion provide an expert update concerning feasibility proteomics, implications generating analyzing large-scale data, recommendations ensure both effective real-world applications.